Obeticholic Acid Non-Response Signals Higher Clinical Risk in Primary Biliary Cholangitis
Highlight
This multicenter study evaluates the prognostic significance of biochemical response to obeticholic acid (OCA) in primary biliary cholangitis (PBC). Non-responders at 12 months face a significantly higher risk of serious clinical events. Despite increasing response rates over time, high OCA discontinuation rates suggest an unmet need for alternative treatment strategies.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.